Aude-Claire Morillon1,2, Debora F B Leite3,4, Shirish Yakkundi1,2, Lee A Gethings5,6, Gregoire Thomas7, Philip N Baker8, Louise C Kenny9, Jane A English1,10, Fergus P McCarthy11,12. 1. INFANT Research Centre, Cork University Hospital, Wilton, Cork, Ireland. 2. Department of Obstetrics and Gynecology, University College Cork, Cork, Ireland. 3. Federal University of Pernambuco, Pernambuco, Brazil. 4. Department of Tocogynecology, Campinas's State University, Sao Paulo, Brazil. 5. Waters Corporation, Wimslow, UK. 6. Manchester Institute of Biotechnology, Division of Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. 7. SQU4RE, 8800, Roeselare, Belgium. 8. College of Life Sciences, University of Leicester, Leicester, UK. 9. Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK. 10. Department of Anatomy and Neuroscience, University College Cork, Cork, Ireland. 11. INFANT Research Centre, Cork University Hospital, Wilton, Cork, Ireland. Fergus.mccarthy@ucc.ie. 12. Department of Obstetrics and Gynecology, University College Cork, Cork, Ireland. Fergus.mccarthy@ucc.ie.
Abstract
INTRODUCTION: Small for gestational age (SGA) may be associated with neonatal morbidity and mortality. Our understanding of the molecular pathways implicated is poor. OBJECTIVES: Our aim was to determine the metabolic pathways involved in the pathophysiology of SGA and examine their variation between maternal biofluid samples. METHODS: Plasma (Cork) and urine (Cork, Auckland) samples were collected at 20 weeks' gestation from nulliparous low-risk pregnant women participating in the SCOPE study. Women who delivered an SGA infant (birthweight < 10th percentile) were matched to controls (uncomplicated pregnancies). Metabolomics (urine) and lipidomics (plasma) analyses were performed using ultra performance liquid chromatography-mass spectrometry. Features were ranked based on FDR adjusted p-values from empirical Bayes analysis, and significant features putatively identified. RESULTS: Lipidomics plasma analysis revealed that 22 out of the 33 significantly altered lipids annotated were glycerophospholipids; all were detected in higher levels in SGA. Metabolomic analysis identified reduced expression of metabolites associated with detoxification (D-Glucuronic acid, Estriol-16-glucuronide), nutrient absorption and transport (Sulfolithocholic acid) pathways. CONCLUSIONS: This study suggests higher levels of glycerophospholipids, and lower levels of specific urine metabolites are implicated in the pathophysiology of SGA. Further research is needed to confirm these findings in independent samples.
INTRODUCTION: Small for gestational age (SGA) may be associated with neonatal morbidity and mortality. Our understanding of the molecular pathways implicated is poor. OBJECTIVES: Our aim was to determine the metabolic pathways involved in the pathophysiology of SGA and examine their variation between maternal biofluid samples. METHODS: Plasma (Cork) and urine (Cork, Auckland) samples were collected at 20 weeks' gestation from nulliparous low-risk pregnant women participating in the SCOPE study. Women who delivered an SGA infant (birthweight < 10th percentile) were matched to controls (uncomplicated pregnancies). Metabolomics (urine) and lipidomics (plasma) analyses were performed using ultra performance liquid chromatography-mass spectrometry. Features were ranked based on FDR adjusted p-values from empirical Bayes analysis, and significant features putatively identified. RESULTS: Lipidomics plasma analysis revealed that 22 out of the 33 significantly altered lipids annotated were glycerophospholipids; all were detected in higher levels in SGA. Metabolomic analysis identified reduced expression of metabolites associated with detoxification (D-Glucuronic acid, Estriol-16-glucuronide), nutrient absorption and transport (Sulfolithocholic acid) pathways. CONCLUSIONS: This study suggests higher levels of glycerophospholipids, and lower levels of specific urine metabolites are implicated in the pathophysiology of SGA. Further research is needed to confirm these findings in independent samples.
Entities:
Keywords:
Fetal growth restriction; Lipidomics; Metabolomics; Placental insufficiency; Pregnancy complication; Small for gestational age infant
Authors: R H Bateman; R Carruthers; J B Hoyes; C Jones; J I Langridge; A Millar; J P C Vissers Journal: J Am Soc Mass Spectrom Date: 2002-07 Impact factor: 3.109
Authors: Warwick B Dunn; David I Broadhurst; Helen J Atherton; Royston Goodacre; Julian L Griffin Journal: Chem Soc Rev Date: 2010-08-17 Impact factor: 54.564
Authors: Richard P Horgan; David I Broadhurst; Sarah K Walsh; Warwick B Dunn; Marie Brown; Claire T Roberts; Robyn A North; Lesley M McCowan; Douglas B Kell; Philip N Baker; Louise C Kenny Journal: J Proteome Res Date: 2011-06-29 Impact factor: 4.466
Authors: S Baig; J Y Lim; A Z Fernandis; M R Wenk; A Kale; L L Su; A Biswas; S Vasoo; G Shui; M Choolani Journal: Placenta Date: 2013-03-05 Impact factor: 3.481
Authors: David Broadhurst; Royston Goodacre; Stacey N Reinke; Julia Kuligowski; Ian D Wilson; Matthew R Lewis; Warwick B Dunn Journal: Metabolomics Date: 2018-05-18 Impact factor: 4.290
Authors: Ray Oliver Bahado-Singh; Ali Yilmaz; Halil Bisgin; Onur Turkoglu; Praveen Kumar; Eric Sherman; Andrew Mrazik; Anthony Odibo; Stewart F Graham Journal: PLoS One Date: 2019-04-18 Impact factor: 3.240
Authors: Pengfei Guo; Tristan Furnary; Vasilis Vasiliou; Qi Yan; Kate Nyhan; Dean P Jones; Caroline H Johnson; Zeyan Liew Journal: Environ Int Date: 2022-02-26 Impact factor: 9.621